Clinical Trial

Integrating the Youth Nominated Support Team (YST) With CBT for Black Youth With Acute Suicide Risk

Completed
View on ClinicalTrials.gov →
Summary
The investigators are modifying and testing the preliminary effectiveness and implementation of the combination of two psychosocial interventions, Cognitive Behavioral Therapy for Suicide Prevention (CBT-SP) and the computer-assisted version of the Youth-Nominated Support Team (eYST). This registration will be for Aim 2 and a pilot randomized clinical trial for Aim 3 will be registered separately. In this phase of the study, CBT-SP+eYST will be tested in an initial open trial (number of youth=6) to examine its feasibility and acceptability. Investigators will recruit Black adolescents that come to an urban emergency department (ED) for suicidal thoughts and/or behaviors to receive the intervention in an outpatient community mental health agency. The study focuses on the acute phase of CBT-SP, which is 12 sessions. Participants will nominate up to 4 caring adults in the participants lives to serve as support persons. These support persons will attend an education/orientation session to learn more about their role and how to support the youth. Youth will be assessed at baseline, 6 weeks, and 14 weeks. Parents will be assessed at baseline and 14 weeks. Support persons will be assessed at baseline and 14 weeks. Fidelity assessments will be completed by clinicians after each CBT-SP session, after the YST psycho-ed session, and weekly to document contact with the support team.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-15; most recent amendment 2026-05-13.
Status change: Recruiting → Completed 2026-05-13
Status change: Not Yet Recruiting → Recruiting 2025-05-06
Trial Details
NCT Number NCT06941311
Lead Sponsor University of Michigan
Collaborators: National Institute of Mental Health (NIMH), MiSide, Children's Hospital of Michigan
Conditions Suicide Prevention
Enrollment 26 participants
Start Date 2025-05-08
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-18